Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Prato – page 22

885 clinical trials in Prato, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Prato at a glance
885
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

885 trials in Prato

Open in trial search

Adenocarcinoma of colon

Recruiting

Study on Temozolomide and Irinotecan for Patients with Stage II/III Colorectal Cancer and Positive ctDNA After Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Malignant melanoma

Recruiting

Study of Vemurafenib, Cobimetinib, and Atezolizumab for Patients with High-Risk, Surgically Removable BRAF Mutated and Wild-Type Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione Melanoma Onlus

Anaemia of chronic disease

Recruiting

Study on Efepoetin Alfa and Darbepoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Darbepoetin Alfa
  • Sponsor:Genexine Inc.

Non-small cell lung cancer stage III+3

Recruiting

Study of Volrustomig and Drug Combination for Patients with Early-stage Resectable Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Recruiting

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Myelofibrosis+1

Recruiting

Study on the Safety and Effectiveness of Navtemadlin and Ruxolitinib for Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Navtemadlin
  • Sponsor:Kartos Therapeutics Inc.

Progressive multiple sclerosis

Recruiting

Study on the Effects of Siponimod on Imaging and Immune Markers in Patients with Progressive Multiple Sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Siponimod
  • Sponsor:Azienda Ospedaliera Universitaria Integrata Verona

Indolent systemic mastocytosis

Recruiting

Study of Elenestinib for Patients with Indolent Systemic Mastocytosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Blueprint Medicines Corp.

Septic shock

Recruiting

Study on the Effectiveness and Safety of IgM-Enriched Immunoglobulin Therapy for Patients with Septic Shock

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Immunoglobulin G
  • Sponsor:Azienda Ospedaliero Universitaria Di Modena

Heart valve operation

Recruiting

Study on the Use of Landiolol Hydrochloride and Sodium Chloride for Patients Undergoing Mitral Valve Surgery to Prevent Low-Cardiac Output Syndrome

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Ospedale San Raffaele S.r.l.

Squamous cell carcinoma of head and neck

Recruiting

Study on Pembrolizumab and Radiotherapy for Patients with Limited Spread of Head and Neck Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Cisplatin
  • Sponsor:Centre Leon Berard

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Prato

What the registry says about research in the country

01 Breast Cancer Research

Extensive clinical trials focusing on hormone receptor-positive and HER2-negative breast cancer treatments, including innovative therapies and maintenance strategies.

  • Advanced treatment combinations
  • Hormone therapy optimization
  • Targeted therapies

Multiple studies evaluating novel drug combinations and personalized treatment approaches for various breast cancer subtypes.

02 Gastrointestinal Oncology

Innovative research in colorectal cancer and pancreatic cancer, exploring new treatment combinations and maintenance therapies.

  • First-line treatments
  • Maintenance strategies
  • Targeted therapeutic approaches

Studies focus on improving survival rates and treatment effectiveness for advanced gastrointestinal cancers.

03 Gynecologic Oncology

Research targeting ovarian cancer and related conditions, with emphasis on platinum-sensitive diseases and novel therapeutic combinations.

  • Maintenance treatments
  • Combination therapies
  • Treatment optimization

Trials exploring new approaches for treating various types of gynecologic cancers with innovative drug combinations.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.